Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
Executive Summary
Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.
You may also be interested in...
Sandoz Still Trying To Sneak Past Amgen’s Stealth Enbrel Patents
Sandoz appeals dismissal of suit seeking a ruling that its Enbrel biosimilar candidate does not infringe patents Amgen licensed from Roche; judge says complaint is premature until an application is filed.
Pfizer’s Xeljanz In Psoriasis Does Best At Dose That Worried FDA
To be competitive in plaque psoriasis, Pfizer’s Xeljanz may need its higher dose – but it will have to convince FDA to approve a dose it rejected due to safety concerns in rheumatoid arthritis.
Pfizer’s Xeljanz In Psoriasis Does Best At Dose That Worried FDA
To be competitive in plaque psoriasis, Pfizer’s Xeljanz may need its higher dose – but it will have to convince FDA to approve a dose it rejected due to safety concerns in rheumatoid arthritis.